Additionally, the prognosis of macular edema may help clinicians evaluate renal function, investigators reported ...

Kalaris is focused on developing TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased ...

For example, KOD’s Tarcocimab Tedromer is an anti-vascular endothelial growth factor [anti-VEGF] antibody biopolymer conjugate that’s currently in Phase 3. This candidate is being tested in ...

DUBLIN--(BUSINESS WIRE)--The "PD-1 x VEGF and PD-L1 x VEGF Bispecific Antibodies: A Business, Pipeline And Competitor Analysis From An Industry Perspective" report has been added to ...